Arcus Biosciences. has been granted a patent for solid forms, solvates, and hydrates of a compound identified as 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile, along with methods for their production and use. GlobalData’s report on Arcus Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arcus Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Arcus Biosciences's grant share as of June 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Solid forms of compound i and their uses
The granted patent US11993584B2 presents a solid form of Compound I, characterized by specific X-ray powder diffraction (XRPD) patterns and differential scanning calorimetry (DSC) profiles. The XRPD analysis reveals distinct peaks at various degrees 2?, including 6.9, 8.2, and 15.7, with additional peaks noted in some claims. The solid form is further defined by its unit cell dimensions obtained through single crystal X-ray crystallography, and it exhibits an endothermic peak at approximately 193°C in the DSC analysis. The patent also includes a pharmaceutical composition that combines this solid form with a pharmaceutically acceptable excipient.
Additionally, the patent outlines a method for treating diseases associated with the adenosine A2A and A2B receptors, particularly targeting various cancers and immune-related conditions. The claims specify that the treatment involves administering a therapeutically effective amount of the solid form of Compound I. Notably, the patent identifies a range of cancers, including prostate, colon, and pancreatic cancers, among others. It also allows for the co-administration of additional therapeutic agents, such as immune checkpoint inhibitors, to enhance treatment efficacy. This comprehensive approach highlights the potential applications of Compound I in oncology and immunotherapy.
To know more about GlobalData’s detailed insights on Arcus Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
